Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by liberte55on Mar 25, 2021 8:12am

234 Views

Post# 32873637

sur le site de sattellos

Announcement: Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine TechnologyJanuary18, 2021Satellos Bioscience is proud to announce that Parent Project Muscular Dystrophy (PPMD), a non-profitorganization leading the fight to end Duchenne Muscular Dystrophy (Duchenne), has committed a $1 million programmatic investment in Satellos Bioscience Inc. to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.The full story behind this exciting announcement by PPMD and Satelloscan be foundhere

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks